China-based Simcere Pharmaceutical Group announced that it will acquire a 51 percent stake in Boda Pharmaceutical. Simcere produces a neuroprotective stroke management medication, and Boda manufactures the only other injectable edaravone products in China. By taking a stake in Boda, Simcere will own the entire injectable edaravone market in the country.
- check out Simcere's release for more